{"id":"t-2345","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"T-2345 works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in regulating blood pressure. This leads to a decrease in angiotensin II levels, resulting in vasodilation and a reduction in blood pressure.","oneSentence":"T-2345 is a small molecule drug that targets the renin-angiotensin system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:12.273Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01494753","phase":"PHASE2","title":"Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2008-06","conditions":"Primary Open Angle Glaucoma","enrollment":30},{"nctId":"NCT02059278","phase":"PHASE3","title":"Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nephron Pharmaceuticals Corporation","startDate":"2014-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":335},{"nctId":"NCT01156012","phase":"PHASE3","title":"Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2009-09","conditions":"Glaucoma","enrollment":404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"T-2345","genericName":"T-2345","companyName":"Nephron Pharmaceuticals Corporation","companyId":"nephron-pharmaceuticals-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"T-2345 is a small molecule drug that targets the renin-angiotensin system. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}